Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia.
about
Silodosin for the treatment of clinical benign prostatic hyperplasia: safety, efficacy, and patient acceptabilityEvidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasiaEmerging and investigational drugs for premature ejaculationA pooled analysis of individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasiaSilodosin is effective for treatment of LUTS in men with BPH: a systematic reviewSafety and efficacy of silodosin for the treatment of benign prostatic hyperplasiaNew clinical evidence of silodosin, an α(1A) selective adrenoceptor antagonist, in the treatment for lower urinary tract symptoms.Silodosin: treatment of the signs and symptoms of benign prostatic hyperplasia.Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia.Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement.Silodosin in the management of lower urinary tract symptoms as a result of benign prostatic hyperplasia: who are the best candidates.Cardiovascular and ocular safety of α1-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms.Silodosin: a review of its use in the treatment of the signs and symptoms of benign prostatic hyperplasia.The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia with α-blockers: focus on silodosin.Advances in understanding and treating premature ejaculation.Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: A European phase IV clinical study (SiRE study).Efficacy and safety of silodosin in the treatment of lower urinary tract symptoms in elderly men taking antihypertensive medications.Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial.Effects of Silodosin and Tamsulosin on the Seminal Vesicle Contractile Response.Premature ejaculation: challenging new and the old concepts.Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH.A prospective longitudinal survey of erectile function status in symptomatic benign prostatic hyperplasia patients treated with dutasteride.Comparison of Two Different α1-Adrenoceptor Antagonists, Tamsulosin and Silodosin, in the Treatment of Male Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective Randomized Crossover Study.Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia.
P2860
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
P2860
Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Ejaculation disorder is associ ...... benign prostatic hyperplasia.
@ast
Ejaculation disorder is associ ...... benign prostatic hyperplasia.
@en
Ejaculation disorder is associ ...... benign prostatic hyperplasia.
@nl
type
label
Ejaculation disorder is associ ...... benign prostatic hyperplasia.
@ast
Ejaculation disorder is associ ...... benign prostatic hyperplasia.
@en
Ejaculation disorder is associ ...... benign prostatic hyperplasia.
@nl
prefLabel
Ejaculation disorder is associ ...... benign prostatic hyperplasia.
@ast
Ejaculation disorder is associ ...... benign prostatic hyperplasia.
@en
Ejaculation disorder is associ ...... benign prostatic hyperplasia.
@nl
P2093
P1433
P1476
Ejaculation disorder is associ ...... benign prostatic hyperplasia.
@en
P2093
Kazuki Kawabe
Masaki Yoshida
Masayuki Takeda
Yukio Homma
P304
P356
10.1016/J.UROLOGY.2010.03.015
P407
P577
2010-05-15T00:00:00Z